

A study to assess the distribution and effect of food and pH on belvarafenib in the blood of healthy adults

Submission date 16/09/2022	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 20/09/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 26/02/2024	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Belvarafenib (the study drug) is an experimental drug being developed for the treatment of certain types of cancer. Belvarafenib being an experimental drug is not yet approved by the health authorities. This study will be conducted in two parts. The purpose of this study is:

Part 1: This part of the study will compare the amount of study drug that enters the circulation of the body (to have an active effect), and how long it takes for the body to get rid of it when given as the original reference tablet formulation (belvarafenib di-hydrochloride salt [HCl]) compared to a new tablet formulation (belvarafenib bis-methanesulfonic acid salt [MSA] formulation), as well as the new tablet formulation given at different doses. Both formulations will be given with a low-fat meal.

Part 2: Food Effect: Part 2 of this study aims to evaluate the effect of food on the absorption of the new tablet formulation of the study drug, and to collect information on any side effects that may occur when the study drug (new tablet formulation) is taken with and without food.

Part 2: pH Effect: The purpose of this part of the study is to assess the effect of rabeprazole (an approved medication that changes the pH in the stomach) on the amount of study drug (new tablet formulation) that reaches the bloodstream, and how long the body takes to get rid of it, when given with a low-fat meal.

Both Part 1 & Part 2: The safety and tolerability of the study drug will be evaluated in both parts of the study.

Who can participate?

Healthy people aged between 18 to 65 years old

What does the study involve?

The study includes the following parts: Part 1, Part 2 (food effect), and Part 2 (pH effect).

Participants will be enrolled in any one part of the study i.e., Part 1, Part 2 (food effect), and Part 2 (pH effect). Both parts of this study have 3 stages:

1. Screening: To see if participants are eligible for the study. Participants will have one clinic visit for screening which will be done 35 days before the first dose of the study drug.
2. Dosing/Confinement: Participants will receive study drugs during this period.

Part 1: Participants will be randomly assigned to one of the two groups, each having two dosing periods. The order in which the participants receive each dosing will be determined by chance.

Group 1a: Participants will receive a single dose of belvarafenib new formulation and original formulation by mouth, after a low-fat breakfast, on Day 1 of Period 1 and Day 1 of Period 2 in one of the two sequences:

Sequence I: Belvarafenib new formulation in Period 1 and belvarafenib original formulation in Period 2

Sequence II: Belvarafenib original formulation in Period 1 and Belvarafenib new formulation in Period 2

Group 1b: Participants will receive a single dose of 50 mg and 200 mg belvarafenib tablets (new formulation) by mouth, after a low-fat breakfast on Day 1 of Periods 1 and 2 in one of the two sequences:

Sequence I: Belvarafenib 50 mg, in Period 1 and belvarafenib 200 mg in Period 2

Sequence II: Belvarafenib 200 mg in Period 1 and belvarafenib 50 mg in Period 2

Part 2: Food effect: Participants will receive a single dose of belvarafenib new formulation by mouth on Day 1 of Period 1 and 2, in one of the two sequences. The order in which the participants receive each dosing will be determined by chance.

Sequence I: Belvarafenib with high-fat breakfast in Period 1 and belvarafenib without breakfast in Period 2.

Sequence II: Belvarafenib without breakfast in Period 1 and belvarafenib with high-fat breakfast in Period 2

Part 2: pH effect: Participants will receive a single dose of belvarafenib new formulation by mouth on Day 1 of Period 1. In Period 2, participants will receive a rabeprazole tablet by mouth on Days 1 to 5 and belvarafenib new formulation on Day 1 after a low-fat breakfast.

During this study, each dose of the medicines will be given in the morning after an overnight fast of at least 8 hours.

Participants will have to be a part of this study for 8 weeks (Part 1) and 7 weeks (Part 2: Food effect and pH effect), not including the screening visit. Participants will have to check in to the study site one day prior to belvarafenib dosing for both parts. There will be 2 clinic confinements visits for each part are as follows:

- Part 1: Clinic confinements of 11 days/10 nights

- Part 2 food effect: Clinic confinements of 11 days/10 nights

- Part 2 pH effect: One confinement lasting 11 days/10 nights; One clinic confinement lasting 15 days/14 night

There will be at least 18 days between each dosing in all the parts of the study.

3. Follow-up: To check on the participants after dosing is finished. Participants will have one outpatient visit 21 to 27 days after the last dose of the study drug for both Part 1 and Part 2 (food and pH effect). A follow-up phone call will be done only if the outpatient visit occurs between 21 and 27 days after the last dose of the study drug.

What are the possible benefits and risks of participating?

Participants will not receive any health benefits from participating in this study, but the information that is learned may help people with cancer in the future.

Participants may have side effects from the drugs used in this study. The known side effects of this drug, as well as potential side effects, are listed below.

Risks associated with belvarafenib:

1. Known Side Effects: Skin changes including different types of rashes and itching
2. Potential Side effects: Injury to the digestive tract, decreased heart function, abnormal electrical conduction within the heart, sensitivity to sunlight, acne, hair loss, constipation, nausea, or the urge to vomit, vomiting, heartburn, fatigue or tiredness, fever, loss of appetite, muscle pain, high blood pressure, severe skin or mucosal reactions, nerve injury, liver injury, kidney injury

Risks Associated with Rabeprazole: Abdominal pain, sore throat, gas, increased chance of infections, constipation

There may be a risk in exposing an unborn child to study the drug, and all risks are not known at this time. Women who are pregnant, become pregnant, or are currently breastfeeding, cannot participate in this study.

Where is the study run from?

F. Hoffmann-La Roche Ltd (USA)

When is the study starting and how long is it expected to run for?

June 2022 to June 2023

Who is funding the study?

F. Hoffmann-La Roche Ltd (USA)

Who is the main contact?

global-roche-genentech-trials@gene.com

Contact information

Type(s)

Public

Contact name

Mr Clinical Trials

Contact details

1 DNA Way

South San Francisco

United States of America

94080

+1 (0)888-662-6728
global-roche-genentech-trials@gene.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

GP44112

Study information

Scientific Title

A phase I, single-dose, randomized, crossover, relative bioavailability and food-effect study and phase I, single-dose, fixed-sequence, crossover, pH-effect study of belvarafenib (GDC-5573) in healthy subjects

Study objectives

The purpose of this study is:

Cohort 1a: To evaluate the influence of a formulation change on belvarafenib exposure by determining the relative bioavailability of belvarafenib following administration of the MSA formulation tablet (test) relative to the HCl formulation tablet (reference) in the fed state (low-fat meal)

Cohort 1b: To evaluate the dose proportionality of belvarafenib exposure following different doses of the MSA tablet formulation administered in the fed (low-fat meal) state

Cohort 2a: To evaluate the influence of food on belvarafenib exposure by determining the exposure of the MSA tablet formulation when administered with a high-fat meal versus the fasted state

Cohort 2b: To evaluate the influence of a proton pump inhibitor on belvarafenib exposure following administration of the MSA tablet formulation in the fed state (low-fat meal) in combination with rabeprazole versus alone

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 13/07/2022, Salus IRB (2111, W. Braker Lane, Suite 100, Austin, Texas, 78758, USA; +1 (0)512 380 1244; salus@salusirb.com), ref: None available

Study design

Single-centre two-part single-dose open-label randomized crossover fixed-sequence relative-bioavailability food-effect pH-effect study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Healthy participants

Interventions

1. Part 1: Cohort 1a, Sequence I: Participants will first receive a single dose of belvarafenib bis-methanesulfonic acid salt (MSA) formulation, 400 milligrams (mg), orally, after a low-fat meal, on Day 1, Period 1. Following an 18-day washout period, participants will then receive a single dose of belvarafenib di-hydrochloride salt (HCl) formulation, 400 mg, orally, after a low-fat meal on Day 1, Period 2.
2. Part 1: Cohort 1a, Sequence II: Participants will first receive a single dose of belvarafenib HCl formulation, 400 mg, orally after a low-fat meal on Day 1, Period 1. Following an 18-day washout period, participants will then receive a single dose of belvarafenib MSA formulation, 400 mg, orally, after a low-fat meal on Day 1, Period 2.
3. Part 1: Cohort 1b, Sequence I: Participants will first receive a single dose of belvarafenib MSA formulation, 50 mg, orally, after a low-fat meal on Day 1, Period 1. Following an 18-day washout period, participants will then receive a single dose of belvarafenib MSA formulation, 200 mg, orally, after a low-fat meal on Day 1, Period 2.
4. Part 1: Cohort 1b, Sequence II: Participants will first receive a single dose of belvarafenib MSA formulation, 200 mg, orally, after a low-fat meal on Day 1, Period 2. Following an 18-day washout period, participants will then receive a single dose of belvarafenib MSA formulation, 50 mg, orally, after a low-fat meal on Day 1, Period 2.
5. Part 2: Cohort 2a, Sequence I: Participants will first receive a single dose oral of belvarafenib MSA formulation, at dose determined in Part 1, following a high-fat meal, on Day 1, Period 1. Following an 18-day washout period, participants will then receive a single oral dose of belvarafenib MSA formulation, at dose determined in Part 1, in a fasted state on Day 1, Period 2.
6. Part 2: Cohort 2a, Sequence II: Participants will first receive a single oral dose of belvarafenib MSA formulation, at dose determined in Part 1, in a fasted state on Day 1, Period 1. Following an 18-day washout period, participants will then receive a single oral dose of belvarafenib MSA formulation, at dose determined in Part 1, following a high-fat meal on Day 1, Period 2.
7. Part 2: Cohort 2b: Participants will first receive a single oral dose of belvarafenib MSA formulation, at dose determined in Part 1, following a low-fat meal on Day 1, Period 1. Following an 18-day washout period, participants will then receive Rabeprazole, 20 mg, orally, after an 8-hour fast, on Days 1 to 5 of Period 2, followed by single oral dose of belvarafenib MSA formulation, at dose determined in Part 1, following a low-fat meal on Day 5, Period 2.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Belvarafenib (GDC-5573)

Primary outcome(s)

1. Cohort 1a: The geometric mean ratio (GMR) and associated 90% confidence intervals (CIs) of maximum observed plasma concentration (C_{max}), concentration versus time curve from time zero extrapolated to infinity ($AUC_{0-\infty}$), and AUC from hour 0 to the last measurable concentration (AUC_{0-t}) following administration of belvarafenib HCl and belvarafenib MSA formulation after low-fat meal
2. Cohort 1b: Dose-normalized C_{max} , $AUC_{0-\infty}$, and AUC_{0-t} following administration of different

dose levels of belvarafenib MSA formulation after low-fat meal

3. Cohort 2a: The GMR and associated 90% CIs of C_{max} , $AUC_{0-\infty}$, and AUC_{0-t} following administration of belvarafenib MSA formulation after high-fat meal and in the fasted state

4. Cohort 2b: The GMR and associated 90% CIs of C_{max} , $AUC_{0-\infty}$, and AUC_{0-t} following administration of belvarafenib MSA formulation alone and co-administered with rabeprazole after low-fat meal

Timeframe: PK outcomes measured using blood samples collected from Day 1 up to Day 14

Key secondary outcome(s)

1. Cohort 1a: Time to C_{max} (t_{max}), apparent terminal elimination rate constant (λ_z), terminal half-life ($t_{1/2}$), apparent systemic clearance (CL/F), and apparent volume of distribution during the terminal phase (V_z/F) following administration of belvarafenib HCl and belvarafenib MSA formulation after low-fat meal

2. Cohort 1b: t_{max} , λ_z , $t_{1/2}$, CL/F , and V_z/F following administration of different dose levels of belvarafenib MSA formulation after low-fat meal

3. Cohort 2a: t_{max} , λ_z , $t_{1/2}$, CL/F , and V_z/F following administration of belvarafenib MSA formulation after high-fat meal and in the fasted state

4. Cohort 2b: t_{max} , λ_z , $t_{1/2}$, CL/F , and V_z/F following administration of belvarafenib MSA formulation alone and coadministered with rabeprazole after low-fat meal

Timeframe: PK outcomes measured using blood samples collected from Day 1 up to Day 14

5. Incidence and severity of adverse events (AEs), incidence of abnormalities in clinical laboratory evaluations, 12-lead ECGs, and vital signs measurements (up to approximately 84 Days)

Completion date

23/06/2023

Eligibility

Key inclusion criteria

1. Males or females of non-childbearing potential, between 18 and 65 years of age, inclusive

2. Within body mass index (BMI) range 18 to 32 kilograms per square meter (kg/m^2), inclusive, at Screening

3. Females will not be pregnant or breastfeeding and must be either postmenopausal or surgically sterile. For all females, the pregnancy test result must be negative at Screening and Period 1 Check-in (Day -1)

4. Negative screening test for latent Mycobacterium tuberculosis (TB) infection by QuantiFERON® TB Gold. Indeterminate results may be confirmed by repeat or by a purified protein derivative (PPD) skin test

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that uncomplicated appendectomy and hernia repair will be allowed
3. History of acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) as determined by the investigator (or designee) at Screening or Period 1 Check-in (Day -1)
4. Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives or 90 days, whichever is longer, prior to study entry
5. Treatment with intravenous antibiotics within 8 weeks or oral antibiotics within 4 weeks prior to Screening or during the entire study duration
6. Use of any drugs known to be moderate or strong inhibitors or inducers of CYP3A, and for Cohort 2b CYP2C19, within 30 days prior to Period 1 Check-in (Day -1) and during the entire study duration
7. Poor peripheral venous access
8. History of malignancy within 5 years prior to enrollment

Date of first enrolment

20/09/2022

Date of final enrolment

19/05/2023

Locations

Countries of recruitment

United States of America

Study participating centre

Labcorp Drug Development

1900 Mason Avenue

Suite 140

Daytona Beach, FL

United States of America

32117

Sponsor information

Organisation

F. Hoffmann-La Roche Ltd

Funder(s)**Funder type**

Industry

Funder Name

F. Hoffmann-La Roche Ltd

Results and Publications**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are not expected to be made available due to participant-level data not being a regulatory requirement.

IPD sharing plan summary

Not expected to be made available